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INTRODUCTION
Although several advances have been made
in improving the surgical, chemo and/or hor-
mone therapies for regulating breast cancers,
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ABSTRACT
The method of cytological examination by
fineneedle aspiration biopsy (FNAB) was devel-
oped clinically in breast cancer and enabled us
to prepare cancer cell nuclei for the detection of
p53 gene mutation. In the expectation that this
method would improve the prediction of postop-
erative prognosis, the observation of 10year
survival for breast cancer patients with p53
gene mutations was done. The DNA of the aspi-
rated cells was examined preoperatively for
gene alterations in 53 patients with breast can-
cer. The p53 protein accumulation, DNA ploidy
pattern, estrogen receptor (ER) , and clinicopa-
thological factors were examined postopera-
tively.
The postoperative followup was conducted
over 10 years and evaluated the status of p53
gene mutation. In 26 patients (49.1%) , 29 p53
gene mutations were shown. p53 protein accu-
mulations and DNA aneuploidy patterns were
detected in 33 (62.3%) and 42 (79.2%) cases, re-
spectively, and both significantly correlated with
p53 gene mutations. With regard to the postop-
erative prognosis, in over 10 years of observa-
tion, the patients who showed p53 mutations
had a significantly worse prognosis in both dis-
easefree survival and overall survival than
those showing negative p53 mutation. A similar
tendency was also seen in patients with his-
tologic grade 3. Using FNAB, the usefulness of
the preoperative detection of p53 gene mutation
was revealed, suggesting its clinical benefits for
predicting a patient's prognosis.
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the mortality rate remains high in Japan and
Western countries as well 1, 2）. Therefore, it is
important to note that the cure rate for breast
cancer patients would improve significantly if
breast cancers could be detected during the
early stage, and patients can be administered a
suitable treatment for better prognoses. Many
clinical methods have been developed for the
early detection of cancers; mass screening pro-
grams are being conducted using mammogra-
phy, ultrasonography, and needle biopsy com-
bined with physical examination 2）. Most of all,
FNAB is regarded as a valuable tool to detect
breast cancer cytologically. Moreover, as we
have mentioned in our previous reports 37）,
since 1994, FNAB has become a more reliable
method to achieve an accurate diagnosis with-
out causing the patient any harm; this is done
by detecting p53 gene mutation, using PCR (po-
lymerase chain reaction) combined with SSCP
(single strand conformation polymorphism)
analysis, and direct nucleotide sequencing.
It has been recently reported that the p53
gene is a multifunctional tumorsuppressor 8）
and that its mutations play an important role in
the development of many common human ma-
lignancies 9, 10）. In case of breast cancer, the fre-
quent genetic alteration of the p53 gene and nu-
clear accumulation of the p53 protein have been
studied in detail 11, 12）. Consequently, in malig-
nant tumor cells, p53 protein localization was
first undertaken to elucidate the link between
p53 gene mutation and the nuclear accumula-
tion of its protein13）. According to Allred et al .14）,
many breast cancers which show nuclear accu-
mulation of the p53 protein are considered to
have a poor prognosis. On the other hand, pri-
mary breast cancers with a p53 gene mutation
are almost always histologically lowgrade and
show undesirable prognoses, regardless of their
p53 protein expression patterns and/or muta-
tional characteristics 15）. Evidence clearly sug-
gests that tumorigenesis results from an accu-
mulation of some genetic abnormalities in po-
tent genes such as p53, BRCA 13, cerb B2,
and cMyc ; therefore, it is logical to evaluate
genetic alterations in an effort to predict bio-
logic behavior 7, 8）. Most of all, with regard to
the p53 gene, the implication for carcinogenesis
is that when p53 function becomes genetically
unstable, this event predisposes to gross
genomic alterations such as gene amplifications,
translocations, and deletions16）. Thus, the tumor
suppressor gene p53 is now well known to play
a crucial role in the development of a wide vari-
ety of human cancers. Particularly in breast
cancer, most mutations are proved to be located
in the evolutionary highly conserved regions of
the p53 gene, which span exons 5 to 8 17, 18）.
Since 1992, to clarify the extent of p53 gene
mutation involvement in tumor development
and to predict the tumor progression, we have
investigated p53 gene mutation in the DNA
samples of tumor cells extracted preoperatively
from breast cancers by FNAB; preoperatively,
this resulted in the improvement of diagnostic
accuracy 3, 4, 6）and in contributing to the early
detection of shortterm relapse of disease 7）.
In the present study, by using PCRSSCP
with direct DNA sequencing, we detected and
analyzed the p53 gene mutations in DNA sam-
ples extracted from the cells that were obtained
from breast cancers by FNAB. This was done
in the expectation that this method would im-
prove the prediction of postoperative prognosis
in breast cancer patients; the DFS and OS rates
were estimated over 10 years of longterm ob-
servation.
PATIENTS AND METHOD
１．Patients and samples
This study comprised 53 randomized
women with primary invasive breast carcinoma
that was diagnosed and treated between 1992
and 1995 at the Sapporo Medical University
Hospital or its affiliated hospitals, without any
evidence of distant metastasis at the time of
surgery . All patients were preoperatively diag-
nosed as having malignant tumors by finenee-
dle aspiration cytology (FNAC) , and the p53
gene mutations in the tumor cells were de-
tected by PCRSSCP and direct DNA sequenc-
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ing. The patients' ages ranged from 26 to 72
years, with a mean age of 50.7 years. The pa-
tients were either treated by mastectomy (45
patients) or breast conserving surgery (8 pa-
tients) . The histological confirmation of nodal
status was available in 49 patients. Lymph node
involvement was determined in the course of
the routine pathological assessment. The re-
sected specimens of each breast cancer were
frozen in liquid nitorogen until use. Fortysix
patients received adjuvant hormone therapies,
and 4 patient received adjuvant chemothera-
pies, while 3 patients received adjuvant chemo
hormone therapies. Medical records of the pa-
tients were reviewed to collect both clinical and
pathological data. The postoperative followup
was conducted at 1～3month intervals during
the first year and at 6～12month intervals
thereafter. The minimal period of followup was
10 years until January 2006. The median follow
up time, defined as the median time between
the primary operation and the date of evalu-
ation, was 12.9 years.
２．DNA extraction
Fiftythree aspirated biopsy specimens con-
sisting of approximately 15×103 cells were
bathed in RPMI1640 medium and then immedi-
ately immersed into liquid nitrogen and stored
at －80 ℃ until assayed. The genomic DNA ob-
tained from each of the 53 patients was pre-
pared by proteinase K digestion and phenol/
chloroform extraction, according to a modifica-
tion of the method of Lyons et al . 19）.
３．PCRSSCP analysis
In this study, as was done previously 36）,
the PCRSSCP analysis was undertaken for the
53 aspirationbiopsied breast cancer specimens;
the mutations in exons 5 to 8 of the p53 gene
were examined in each cancer cell. The se-
quences of the primers used for this PCR were
modified based on the same sequences de-
scribed in other studies 11, 20）: exon 5, sense
5’TTCCTCTTCCTTGCACTACTCC3’and
antisense 5’CAGCTGCTCACCATCGCTATA3’; exon 6,
sense 5’TTGCTCTTAGGTCTGGCCCCTCCTCAG3’and
antisense 5’CAGACCTCAGGCGGCTCATAGG3’; exon 7,
sense 5’GTGTTATCTCCTSGGTTGGC3’and antisense
5’CAAGTGGCTCCTGACCTGGA3’; and exon 8,
sense 5’AGTGGTAATCTACTGGGACGG3’and antisense
5’ACCTCGCTTAGTGCTCCCTG3’. A200ng
genomic DNA sampled from each of the aspi-
rated cells was amplified in 25 µl volumes of the
buffer recommended by PerkinElmer Cetus
(Norwalk, CT) , which contained 1 mM MgCl2 ,
1 unit of Taq DNA polymerase, and 1 µl of [ α
32P ] d CTP (3000 Ci/mmol, 10 Ci/ml; Amersham
Japan, Tokyo) .
Subsequently, using a thermal programmer
(Nippon Genetic Co., Tokyo) , 35 cycles were
performed for each sample, each involving de-
naturation at 94℃ for 30 s, annealing at 55℃ for
30 s, and extension at 72℃ for 1 min. Following
this, a 2µl volume of each PCR product was di-
luted 100fold with a sequencing gelloading
buffer (98% deionized formamide, 10 mM EDTA
pH 8.0, 0.0025% xylen cyanol, 0.025% bromophe-
nol blue) that was then applied (1µl/lane) to a
6 % neutral polyacrylamide gel. Electrophoresis
was performed at 40 W for 3.5５h with fan
cooling. Subsequently, the gel was fixed in ace-
tic acid (10%) , dried, and exposed to Xray film
for 612 h at 80 ℃.
４．Direct DNA sequencing of PCR products
In order to detect the DNA sequences, the
shifted bands in exons 5 to 8 obtained from bi-
opsy specimens, were eluted from the poly-
acrylamide gel and amplified by a PCR by using
the same primers as those used for the PCR
products purified with SUPRECTM02 (Takara
Shuzo, Kyoto) .
Sequencing was performed by the dideoxy
termination method by using a 7DEAZA Se-
quencing KIT, Version 2.0 (Takara Shuzo) , as
has been described before 4, 5）.
５．Immunohistochemical analysis
For the immunohistochemical study, Pab
1901, an antibody against the p53 protein was
used. PAb 1801 (Oncogene Science, Inc.,
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Manhasset, NY) is a murine monoclonal anti-
body against human p53 and recognizes both
the wildtype and mutant forms of the p53 pro-
tein. To detect the p53 protein nuclear accumu-
lation, PAb 1801 was used, as we have previ-
ously reported 21）; for immunoperoxidase stain-
ing, 6 µmthick frozen sections from each of the
resected tumors were subsequently placed onto
polyLlysinecoated glass slides and fixed in
chilled acetone. The slides were airdried for 1
h, after which the primary antibodies were ap-
plied in accordance with the standard avidin
biotin system recommended by the vendor
(Nichirei, Tokyo) . The sections were adequately
stained with 3, 3iaminobenzidine (Sigma
Chemical, St. Louis, MO) , and the nuclei were
counterstained with methyl green. Phosphate
buffered saline containing 1% bovine serum al-
bumin was used as the negative control instead
of the primary antiserum.
６．DNA ploidy pattern
To examine the DNA ploidy pattern, nuclei
from the surgically resected breast cancers
were isolated from each of the frozen tissue
specimens with 0.1% Triton X100 (Sigma) . The
isolated nuclei were treated with 0.1% RNase
(Sigma) , stained with 50 µg/ml propidium io-
dide (Sigma) , and filtered through nylon mesh;
each sample was immediately analyzed using a
FACSIV cell sorter (Becton Dickinson ,
Mountain View, CA) .
７．ER levels
The ER content of the cancer tissue was
determined by a dextrancoated charcoal assay
(Biomedical Laboratories, Tokyo) , and a concen-
tration greater than 5 fmol/mg of the ER pro-
tein was considered to be positive.
８．Statistical analysis
Fisher's exact tests were used to estimate
the association of the clinicopathological vari-
ables, p53 gene mutation, DNA aneuploidy pat-
terns, and the ER value. DFS was calculated
from the date of operation to the date of recur-
rence, and OS was calculated from the date of
operation to the date of death. Survival analyses
were performed according to the KaplanMeier
method. Comparison of the survival between
groups was performed using the logrank test.
Cox proportional hazard analysis was used for
univariate and multivariate analysis to explore
the effect of variables on survival and estimat-
ing the hazard ratio (HR) and 95% confidence in-
terval (CI) . The Statistical Analysis Systems
(SAS) software (SAS Institute Inc., Cary, NC,
USA) was used for all statistical analyses. A sig-
nificant difference was determined when the P
value was less than 0.05 .
RESULTS
The clinical and molecular biological fea-
tures of the 53 breast cancer patients are listed
in Table 1. Of these patients, 28 were premeno-
pausal patients (mean age, 40.3 years) , and 25
were postmenopausal patients (mean age, 63.0
years) . They were all classified into clinical
stages from I to IIIA and into histologic grades
from 1 to 3 . In the histological examination, 39
patients had papillotubular carcinomas, 10 had
solidtubular carcinomas, and 4 had scirrhous
carcinomas. With regard to the nuclear p53 pro-
tein accumulations, positively stained cancer
cells were found in 33 patients (62.3% ; 33 of 53),
and negatively stained ones, in 20 patients
(37.7%) . In hormone receptor investigation, the
ER status was available for all patients; ER posi-
tive tumors were seen in 33 patients (62.3% ; 33
of 53) , and ER negative tumors, in 20 patients
(37.7%) . The examination of the DNA ploidy
pattern revealed that there were 11 DNA dip-
loid cancers (20.8% ; 11 of 53) and 42 aneuploid
cancers (79.2%) . Regardless of the point muta-
tion pattern, almost all breast cancer patients
who had p53 mutations showed DNA aneu-
ploidy patterns (96.2% ; 25 of 26) and tested posi-
tive for nuclear p53 protein staining (73.1% ; 19
of 26) as well .
Consequently, p53 protein accumulations
and DNA aneuploidy patterns were significantly
correlated with p53 gene mutation (P <0.01 and
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Table １ Clinical and biological features of the ５３ breast cancer patients
Patient
No．
Age
／
Menopause
Clinical
stage* Histology
+ Histologic
grade§
p５３
mutation
／staining
ER
DNA
ploidy
pattern‖
Relapse**
１ ６４／－ IIA Pt １ －／－ － Ａ －
２ ４９／＋ I Pt １ －／－ － Ｄ －
３ ５９／－ IIA Sc ２ ＋／＋ ＋ Ａ －
４ ６４／－ IIIA Pt ３ ＋／＋ － Ａ －
５ ６１／－ I Pt １ －／－ ＋ Ａ －
６ ４５／＋ IIA Pt １ －／＋ ＋ Ａ －
７ ５１／＋ I St １ －／－ ＋ Ｄ －
８ ５６／－ IIB Pt ３ ＋／＋ ＋ Ａ －
９ ４９／＋ IIA Pt １ －／－ ＋ Ａ －
１０ ４３／＋ IIIA Pt ３ ＋／＋ － Ａ ＋
１１ ６７／－ I Pt １ －／－ － Ｄ －
１２ ３０／＋ IIIA Pt ３ ＋／＋ ＋ Ａ ＋**
１３ ６４／－ IIA Pt １ －／＋ ＋ Ａ －
１４ ４４／＋ I Pt ２ －／－ － Ａ －
１５ ５０／＋ I Pt １ －／＋ ＋ Ｄ －
１６ ６６／－ IIIA Pt ３ ＋／－ － Ａ －
１７ ２６／＋ I St １ －／＋ ＋ Ｄ －
１８ ５１／－ IIB Pt ２ ＋／－ － Ａ ＋
１９ ６１／－ IIB St ３ ＋／＋ ＋ Ａ －
２０ ４８／＋ IIA Pt ３ －／－ － Ａ －
２１ ４４／＋ IIIA Pt ２ －／＋ ＋ Ａ －
２２ ５１／＋ I Pt １ －／＋ － Ｄ －
２３ ３３／＋ I Pt １ －／＋ ＋ Ｄ －
２４ ６８／－ IIIA Pt ３ ＋／＋ － Ａ ＋**
２５ ４５／＋ I St ３ ＋／＋ ＋ Ａ －
２６ ４９／＋ IIB Pt ２ ＋／－ － Ａ ＋
２７ ７２／－ IIB Pt ２ ＋／＋ － Ａ －
２８ ６１／－ I Pt １ －／＋ ＋ Ａ －
２９ ４８／＋ IIIA Sc ２ ＋／－ ＋ Ａ －
３０ ２７／＋ I Pt １ －／－ ＋ Ｄ －
３１ ３３／＋ IIB Pt ２ ＋／＋ ＋ Ａ －
３２ ５２／－ IIIA St ３ ＋＋／＋ － Ａ ＋**
３３ ６６／－ IIIA St ３ ＋／＋ － Ａ －
３４ ７０／－ I Pt １ －／－ － Ａ －
３５ ５８／－ I Pt １ －／－ － Ｄ －
３６ ３０／＋ I Pt １ －／＋ ＋ Ａ －
３７ ６１／－ IIIA Sc ３ ＋＋／＋ ＋ Ａ ＋
３８ ６３／－ IIIA Pt ３ ＋＋／＋ ＋ Ａ ＋**
３９ ４４／＋ I Pt １ －／＋ ＋ Ａ －
４０ ３１／＋ I Pt １ －／＋ ＋ Ａ －
４１ ２９／＋ I Pt １ －／－ ＋ Ｄ －
４２ ６７／－ I St １ ＋／＋ ＋ Ａ －
４３ ５８／－ I Pt ３ ＋／－ ＋ Ａ －
４４ ３７／＋ I St １ －／＋ ＋ Ａ －
４５ ５９／－ IIB St ２ ＋／＋ ＋ Ａ －
４６ ６８／－ IIA Pt １ －／－ － Ａ －
４７ ３６／＋ IIA Pt ２ ＋／＋ ＋ Ａ －
４８ ３１／＋ IIA Pt ２ －／＋ ＋ Ａ －
４９ ４７／＋ IIIA St ３ ＋／－ － Ａ ＋**
５０ ７１／－ IIIA Pt ２ ＋／－ ＋ Ｄ －
５１ ３５／＋ IIA Pt ２ ＋／＋ ＋ Ａ －
５２ ４３／＋ I Pt １ －／＋ ＋ Ａ －
５３ ６８／－ IIIA Sc ３ ＋／＋ － Ａ ＋**
* Clinical stage was determined by the TNM classification of the Japanese Breast Cancer Society ３９）．
＋ PT ＝ papillotubular carcinoma； St ＝ solidtubular carcinoma; Sc ＝ scirrhous carcinoma．
§ Histologic grade was determined according to the system based on a modified WHO classification ４０）．
‖ Ａ＝ aneuploid；Ｄ＝ diploid．
** Death by recurrence of breast cancer．
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P <0.001, respectively) . The adjuvant therapy
provided to patients as postoperative treatment
was decided on the basis of their lymphonodal
status, menopausal status, and the level of ER;
consequently, 53 patients were administered
hormone therapy, chemotherapy, and chemo
hormone therapy for 2 or 3 years after obtain-
ing their informed consent. In all cases of recur-
rence, regardless of whether patients had p53
gene mutation or were p53 protein positive,
they have recieved adequate therapies until
their endstages.
However, no adjuvant therapies signifi-
cantly affected the favorable prognosis of pa-
tients with recurrent cancer (data not shown) .
Moreover, of 10 patients with recurrence, 6 pa-
tients (60.0% ; 6 of 10) tested positive for p53
mutation and showed DNA aneuploidy pattern
as well, besides having advanced clinical stage
IIIA, histological stage 3, and p53 protein accu-
mulations (83.3% ; 5 of 6) and being ER positive
(83.3% ; 5 of 6) ; these patients reached the ter-
minal stages within 10 years after the initial op-
eration. With respect to the ER status, many re-
current breast cancers were shown to be ER
negative (70.0% ; 7 of 10) , and 4 ER negative pa-
tients (66.7% ; 4 of 6) died of recurrent cancer.
As shown in Table 2, among 53 breast can-
cer patients 26 showed p53 gene mutation
(49.1% ; 26 of 53) , while no mutation was de-
tected in 27 (50.9%) patients. In total, 26 of the
53 breast cancers revealed 29 mobility shifts in
the PCRSSCP analysis. The characteristics of
the p53 gene mutation were identified by the di-
rect sequencing of the PCRamplified exons
from 5 to 8, as listed in Table 2. The positions
and incidence of the mutations were distributed
as follows: exon 5 (8 samples, 27.6%) , 6 (5 sam-
ples, 17.2%) , 7 (10 samples, 34.5%) , 8 (6 samples,
20.7%) ; these included point mutations such as
Table ２ p５３ gene mutation in aspirationbiopsied breast cancer specimens
Patients
No．
p５３
protein staining
p５３ gene mutation
Exon／Codon base change （Amino acid）
３ ＋ ６／２２０ TAT(Tyr) →TGT(Cys)
４ ＋ ７／２４８* CGG(Arg) →CAG(Gln)
８ ＋ ７／２３４ TAC(Tyr) →TGC(Cys)
１０ ＋ ５／１７５* CGC(Arg) →CAC(His)
１２ ＋ ５／１７５* CGC(Arg) →CAC(His)
１６ ＋ ８／２７９ GGG(Gly) →GAG(Glu)
１８ ＋ ５／１５８ CGC(Arg) →CC**
１９ ＋ ７／２３８ TGT(Cys) →TAT(Tyr)
２４ ＋ ８／２８２* CGG(Arg) →CAG(Gln)
２５ ＋ ５／１４６ TGG(Trp) →TGA(Stop)
２６ － ８／２７５ TGT(Cys) →TTT(Phe)
２７ ＋ ７／２４８* CGG(Arg) →CAG(Gln)
２９ － ７／２３１ ACC(Thr) →ATC(Ile)
３１ ＋ ８／２７９ GGG(Gly) →GG**
３２ ＋ ７／２４８* CGG(Arg) →TGG(Trp)
８／２８２ CGG(Arg) →CG**
３３ ＋ ７／２３６ TAC(Tyr) →TGC(Cys)
３７ ＋ ５／１７５* CGC(Arg) →CAC(His)
７／２４８* CGG(Arg) →CAG(Gln)
３８ ＋ ６／２０４ GAG(Glu) →TAG(Stop)
８／２８２* CGG(Arg) →TGG(Trp)
４２ ＋ ７／２４４ GGC(Gly) →GAC(Asp)
４３ － ５／１７６ TGC(Cys) →TTC(Phe)
４５ ＋ ６／１９２ CAG(Gln) →TAG(Stop)
４７ ＋ ６／１９７ GTG(Val) →GAG(Glu)
４９ ＋ ７／２７３* CGT(Arg) →CTT(Leu)
５０ － ６／２２０ TAT(Tyr) →TGT(Cys)
５１ ＋ ５／１７７ CCC(Pro) →CGC(Arg)
５３ ＋ ５／１５８* CGC(Arg) →CAC(His)
* CpG
** deletion
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20 transitions (69.0% ; 20 of 29) , 6 transversions
(20.7% ; 6 of 29) , and 3 deletions (10.3% ; 3 of 29).
Of the 26 basepair substitutions, the more
prominent feature was G to A transition (60.0% ;
12 of 20) compared to A to G (20.0% ; 4 of 20)
and C to T transitions (20.0% ; 4 of 20) , i. e., 20
transitions (69.0% ; 20 of 29) showed G : C to A :
T , A : T to G : C or C : G to T : A patterns. In 6
cases of transverse mutations, the G to T nu-
cleotide change pattern was the predominant
substitution (4 samples, 66.7%) , and the others
were T to A and C to G. With regard to 3 dele-
tions (10.3% ; 3 of 29) , all were deletions of the
nucleotide guanine. Of the 20 transitions, 10 mu-
tations (50.0% ; 10 of 20) occurred in a CpG dinu-
cleotide sequence, which is known to be the hot
spot for p53 gene mutations in breast cancers14）.
Of 10 patients with recurrence, 8 showed
methylation at CpG sites (80.0% ; 8 of 10) , and 5
patients who died within 10 years all had CpG
mutations.
Our findings from the direct DNA sequenc-
ing of the PCR product are consistent with
those in a previous report that indicates that
most gene mutations are distributed evenly
from exons 4 to 8 22）.
Fig．１ KaplanMeier curves for DFS (left) and OS (right) in breast cancer patients according to
p５３ genemutations．
Fig．２ KaplanMeier curves for DFS (left) and OS (right) in breast cancer patients with different
histological grades．
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As shown in Fig. 1 and Fig. 2, the survival
times of breast cancer patients, such as FDS
and OS, were proved to be closely related to the
presence of p53 gene mutation or an aggressive
histologic grade in the cancer cells. After a me-
dian followup period of 13.6 years, the postop-
erative 10year DFS and OS were 64.0% and
76.0% , respectively, in cases with p53 gene mu-
tation. While in the case of the absence of p53
gene mutation, the 10year DFS and OS were
96.4% and 100% , respectively. Consequently,
the patients who tested positive for p53 muta-
tion had a significantly worse prognosis in
terms of both DFS and OS (P=0.0335 and
0.0062, respectively) than those who tested
negative for it. Furthermore, patients with his-
tologic grade 3 also showed a statistically worse
prognosis than those with grade 1 (DFS, P =
0.0124 and OS, P =0.0003, respectively) . On the
other hand, there was no statistically significant
difference between those who tested positive
and those who tested negative for p53 staining,
and between those who tested positive and
those who tested negative for ER. In addition,
the menopausal status of patients also showed
no significant relationship with other clinical and
cell biological factors. However, in terms of the
DNA ploidy pattern and clinical grade, patients
with aneuploidy pattern showed the tendency
of worse prognosis than those with a diploidy
pattern, and those with clinical grade IIIA
showed better prognosis than those with grade
I and/or IIA. With regard to the prognosis of
breast cancer patients, those who showed clini-
copathologically aggressive grade such as aneu-
ploidy, histologic grade 2 or 3, and clinical stage
IIB or IIIA tested positive for p53 mutaions and
had worse prognosis. Meanwhile, the p53 pro-
tein accumulation did not affect the patients'
survival rate statistically; however, it was pre-
sent in 7 patients with recurrent cancer and p53
mutation (7 of 10 ; 70.0%) . Thus, the close rela-
tionship between p53 mutation and p53 protein
accumulation was indeed suggested. However,
in this study, although the cancer patients with
p53 mutation proved to have a significantly
worse prognosis, cases in which the p53 protein
accumulated showed mostly good survival rates.
Univariate analysis by Cox proportional
hazards model revealed that in the DFS of post-
operative breast cancer patients, the prognosis
was significantly worse for patients with p53
mutation (HR 5.183, P = 0.0375) and histologic
grade 3 (HR 3.516, P = 0.0076) (Table 3) . How-
ever, the result of the multivariate analysis for
the clinicobiological factors of patients showed
that although there was a tendency of unfavor-
able prognosis in patients with p53 mutation, ag-
gressive histologic grade and clinical stage, and
DNA aneuploidy pattern, there was no statisti-
cally significant evidence of this in DFS and OS
(data not shown) .
DISCUSSION
Since first reported by Martin and Ellis 23）,
FNAB has been well established as a conven-
Table ３ Univariate analyses of DFS in breast cancer patients
Variables Categories HR* ９５ ％ CI ** P value
menopause ＋ ／ － １．０２２ ０．９７３ － １．０２２ ０．３７８５
ER ＋ ／ － ０．３７７ ０．１０６ － １．３３８ ０．１３１２
DNA ploidy A ／ D ND ＋ ND ＋ ０．９９３９
Histologic grade １，２／３ ３．５１６ １．３９７ － ８．８５０ ０．００７６
Clinical stage I ，IIA，IIB／ IIIA ０．９９１ ０．５９８ － １．６４２ ０．９７３１
p５３ protein staining ＋ ／ － １．０５９ ０．２９９ － ３．７５５ ０．９２９０
p５３ gene mutation ＋ ／ － ５．１８３ １．１００ － ２４．４２５ ０．０３７５
**hazard ratio．
**confidence interval．
＋ ND ＝ not determined because no patients with diploid patterns reccured．
８ T．SATO et al.
ient and reliable method for the diagnosis of
breast cancers.
Furthermore, the cytological information by
FNAC provides useful preoperative information
unlike pathological information, which is ob-
tained after surgical excision 24）. If the informa-
tion concerning the risk of recurrence, in terms
of chemosensitivity or drug resistence, could be
obtained preoperatively, it would be of great
clinical value to indicate the optimal adjuvant
and/or neoadjuvant treatment. Although the
prognostic value of microscopic information pro-
vided by FNAB has been emphasized, the much
valuable additional advantage of gene mutation
in aspirated cells was considered to be a good
prognostic value 25）. Thus, with the introduction
of PCR, which has become applicable to small
DNA samples obtained by FNAB 3, 4, 6）, p53 gene
mutation is regarded as a potent predictor of
poor postoperative prognosis in breast cancer
patients 8）. In particular, in our previous pa-
per5, 6）, we emphatically reported that the detec-
tion of p53 gene mutations in aspirated biopsy
specimens of breast cancers was helpful for an
accurate and rapid cytological diagnosis, which
might reflect the prognosis.
Mutant p53 was clearly known to be the
most commonly altered protooncogene in
breast cancer 26）. Recently, abnormal levels of
the p53 gene product have been found by rou-
tine immunohistochemical methods in 19% －
58% of breast cancer tissues 27, 28）, and the mo-
lecular analysis of samples with immunodetect-
able protein confirmed in most cases the pres-
ence of point mutations within the gene. In gen-
eral, p53 mutations are present in 20% － 40%
of all breast cancers 11, 1315, 29）. In this study, the
frequency of mutation that we found is compa-
rable to the rate of p53 overexpression ob-
served immunohistochemically. Therefore, p53
overexpression was rarely observed in the pa-
tients with no p53 mutation.
On the other hand, according to Kalogeraki
et al . 30）, in case of FNA specimens, p53 over-
expressions were found in 45% of breast cancer
patients. In the present study, p53 overexpres-
sions were shown in 62.3% patients.
All of the p53 genetic changes that we ob-
served were mainly missense mutations; 26
were point mutations, with the exception being
3 onebase pair deletions (10.3%) that were de-
tected in 24 breast cancers. Among point muta-
tions, a stop codon was produced in only 3 cases
(10.3%) . Of 29 p53 gene alterations in exons 5 to
8, 20 were missense mutations, and 3 patients
showed nonsense mutations, which involved an
inframe deletion of one base pair. Of the 20
transition mutations, 16 were changes from G :
C to A : T . Such a prevalence of G : C to A : T
substitutions in breast cancers was also ob-
served by other researchers 12）. On the whole,
as shown in table 2, the mutation spectrum we
found in breast cancer appears more complex
compared to other tumor types 17, 31）. The occur-
rence of spontaneous base substitutions may
contribute to the appearance of various muta-
tion patterns. In the present study, the promi-
nent mutations were the association of G : C to
A : T and C : G to T : A transitions (20 of 29 ;
69.0%) , and these occurred frequently (9 of 10 ;
90.0%) at the CpG dinucleotide sites (3 at codon
175, 4 at codon 248, and 2 at codon 282) , which
are known to be hot spots for mutations in the
p53 gene for breast cancer.
However, the mutation at codon 158, known
as a novel hot spot, was not detected in this
study. Spontaneously occurring deamination at
methylated CpG sites is a general mechanism
accounting for C to T and G to A changes 32）
and has been indicated as an endogenous cause
of somatic mutations in the p53 gene 33）. As
Esteller et al . 34）demonstrated, CpG island hy-
permethylation has been described in almost
every tumor types; this hypermethylation is
found in the promoter regions of tumorsup-
pressor genes and is now established as an im-
portant mechanism for gene inactivation.
With regard to the change in the p53 gene
of the nuclei in cancer cells, the association of
mutations in the p53 gene and DNA aneuploidy
pattern was found in 25 breast cancer patients
(47.2% ; 25 of 53) , while only one case of DNA
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ploidy pattern with the p53 mutation was de-
tected (1.9% ; 1 of 53) , suggesting a complemen-
tary effect of p53 gene alterations in breast can-
cer tumorigenesis. DNA aneuploidy, which was
predominant in various malignant tumors35）,
might represent an early and critical event in
such a process. According to the NIH consensus
conference 36）, the DNA ploidy status was con-
sidered to be one of the most significant prog-
nostic factors of the early stage in breast cancer
patients. In addition, p53 gene alteration ap-
pears to be particularly involved in more severe
tumor cell transformation. On the other hand, in
the present study, almost all patients with clini-
cal stage I cancers tested negative for p53 mu-
tations (19 of 22 ; 86.4%) and 92.9% (13 of 14) of
the patients with stage IIIA tumors tested posi-
tive for p53 mutations, suggesting that these
may be relevant to the progression of malig-
nancy to a higher clinical grade. Furthermore,
the histologic grade also appears to be related
to the characteristics of tumor malignancy, indi-
cating that the morphology and biology of
breast cancer are closely linked. Such a ten-
dency was observed in our study, e.g., DNA dip-
loidy patterns were mainly shown in clinical
stage I (10 of 22 ; 45.5%) and also in histologic
grade 1 (10 of 24 ; 41.7%) . In fact, 42 patients
with DNA aneuploidy patterns showed 25 p53
gene mutations (59%) , while 1 patient showed
DNA diploid status with p53 mutation, clinical
stage IIIA, and histologic grade 2 and did not
experience recurrence. In spite of adequate ad-
juvant therapies, patients with p53 mutation
showed worse prognosis.
In the observation of 10year survival for
breast cancer patients with p53 gene mutations
in cancer cells aspirated from their tumors,
postoperative prognosis was significantly corre-
lated with p53 gene mutation and with aggres-
sive histologic grade 3. Furthermore, advanced
clinical stage, such as IIIA, was closely related
with p53 gene mutation, ER negative status,
DNA aneuploidy pattern, and histologic grade 3.
These results were consistent with those of
other reports in case of various solid tu-
mors37, 38）. With regard to the ER status in pa-
tients, regardless of the p53 gene status and
other clinicohistological factors, the positive re-
ceptor status is particularly related with a bet-
ter postoperative prognosis in DFS rather than
OS. The better DFS rate might be attributed to
the effect of hormonal adjuvant therapy.
FNAC is a very useful examination and is
routinely performed for the diagnosis of breast
tumors and provides suitable material for both
cytologic examination and DNA analysis. Re-
cently, there appears to be a growing move-
ment in favor of core needle biopsy (CNB) over
FNAC in detecting breast cancer. However,
FNAC has some advantage over CNB, including
simplicity, costeffectiveness, and lower inva-
siveness. Moreover, FNAC permits numerous
multidirectional passes through the mass, but a
CNB device allows for only 1 monodirectional
sample; FNAC was the more sensitive method
for detecting cancer cells. Consequently, the ge-
netic analysis of FNAB materials reveals impor-
tant information such as the risk of recurrence,
particularly shortterm relapse, and the progno-
sis. Further longterm investigations concerning
these p53 gene mutations and the determination
of their biological and prognostic significance in
breast cancer are necessary in a large number
of examined cases.
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